Skip to main navigation
  • Careers
  • Contact

Menu

Skip to content
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • SEC Filings
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Estimates
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • ADCs
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • ZTlido™
      • RTX
  • Translational Efficiencies

News Releases

fundamentals sub menu

  • Fundamentals

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

Mar 22, 2019

CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

Mar 11, 2019

Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

Mar 11, 2019

Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences

Feb 25, 2019

Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program

Feb 12, 2019

Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019

Jan 22, 2019

Scilex Announces Addition of ZTlido® to Express Scripts National Formularies

Jan 14, 2019

Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1)

Jan 14, 2019

Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference

Jan 04, 2019

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Email Page
Clinical Trials
clinicaltrials@sorrentotherapeutics.com
Investors
investors@sorrentotherapeutics.com
Business Development
business@sorrentotherapeutics.com
Media Requests
mediarelations@sorrentotherapeutics.com
© 2017 Sorrento Therapeutics, Inc. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • DMCA
  • Trademarks
  • Linking Policy
  • LinkedIn
MENU
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Analyst Coverage
      • Estimates
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • Quarterly Results
      • Fundamentals
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Investor Contact
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • Antibody Drug Conjugates (ADCs)
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • RTX
      • ZTlido™
  • Translational Efficiencies
  • Careers
  • Contact